Cepheid has announced that its Xpert HCV molecular test to detect hepatitis C at the point of care has been greenlit for the US market.
The company has received FDA De Novo marketing authorisation and Clinical Laboratory Improvement Amendments (CLIA) Waiver approval for Xpert HCV which detects the hepatitis C virus RNA directly from a human capillary whole blood (fingerprick) sample. The Xpert HCV test is performed on the GeneXpert Xpress system.
In the United States, 2.4 million people are estimated to be living with hepatitis C and more than half of the people with HCV do not know that they have the virus. The Viral Hepatitis National Strategic Plan for the United States calls for greater than 80% of people with hepatitis C to achieve viral clearance by 2030. Currently, the clinical care pathway for detection of hepatitis C faces many barriers, including complicated multi-step diagnostic algorithms based on antibody screening and RNA confirmation. These algorithms require centralised testing technologies that may result in treatment delays and could discourage at-risk populations from accessing testing and receiving care. Xpert HCV can accurately detect active HCV infection from individuals at risk and/or with signs and symptoms of HCV infection with or without antibodies to HCV from a capillary blood sample.
"This simple to use test detects the full range of known HCV genotypes in about an hour and can be performed on a small volume of blood collected via fingerstick," said David H Persing MD PhD, Cepheid's Chief Medical and Scientific Officer. "This is the first HCV RNA detection technology sensitive enough for active case finding at the point of care. This enables diagnosis of HCV and facilitates timely linkage to care within a single clinic visit - and with this, the potential for treating more people with HCV," said Vitor Rocha, President of Cepheid.